|Day Low/High||0.05 / 0.05|
|52 Wk Low/High||0.02 / 0.75|
Revenue Up 107 Percent Year-Over-Year; U.S. Sales Increase 123 Percent
Increased Diameter May Allow 10 Percent Increase in Aorfix-Treatable AAA Cases
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DENN, HCAP, ICCC, MITK, UBNT Downgrades: ARDM, ENLK, LB, MRCC, RICK, SMI, SRT Initiations: EVAR, VUZI, ZOES Read on to get TheStreet Quant Ratings' detailed report:
Three-year Contract Expands Access of Aorfix to Prestigious Academic Hospitals
AorFlex Delivery System Launched in Second Largest Standalone Endovascular Aneurysm Repair Market Through Exclusive Distribution Partner
Revenue Up 66 Percent Year-Over-Year; U.S. Sales Increase 125 Percent
Full Year Aorfix(TM) Revenue More Than Doubled Over 2013
Will Evaluate Clinical Outcomes of EVAR With Aorfix(TM) in Broad Cross-Section of AAA Patients
2014 Global Aorfix(TM) Revenue More than Doubled Year-over-Year
Positive Outcomes in Abdominal Aortic Aneurysm Patients With Challenging Anatomies Reinforce Clinical Value of Aorfix
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.